Google recently revealed its plans for TxGemma, a series of open AI models aimed at enhancing drug discovery. These models will be able to interpret regular text and analyze therapeutic entities like proteins and chemicals. The initiative seeks to streamline the lengthy and costly process of drug development by providing researchers with tools to evaluate potential therapies' effectiveness and safety. However, despite the enthusiasm from big pharma, the actual impact of AI in drug research so far has been mixed, with notable clinical trial failures and varying accuracy in existing AI systems.
The development of therapeutic drugs from concept to approved use is a long and expensive process, so we're working with the wider research community to find new ways to make this development more efficient.
While there have been some successes, AI has not provided an immediate magical solution in the lab.
Still, big pharma - and investors - appear to be enthusiastic about the tech's potential.
Google announced that it's developing a collection of "open" AI models for drug discovery called TxGemma.
Collection
[
|
...
]